创源股份 reported revenue of ¥1.08B for the period ended 2026-06-30, +8.6% year on year. Net income was ¥0.01B, a 0.5% net margin on a 35.3% gross margin. The largest revenue line is 文化创意类 at 65% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.08B | +8.6% |
| Gross profit | ¥0.38B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.01B | -92.3% |
| Gross margin | 35.3% | Net margin 0.5% |
| Revenue Q/Q | +17.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 文化创意类 | ¥0.71B | 65.2% |
| 运动健康类 | ¥0.37B | 34.2% |
| 其他(补充) | ¥0.01B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.70B | 64.7% |
| R&D | ¥0.03B | 3.2% |
| SG&A | ¥0.28B | 25.8% |
| Tax & other | ¥0.02B | 1.7% |
| Item | Amount |
|---|---|
| Total assets | ¥2.04B |
| Total liabilities | ¥1.20B |
| Shareholders' equity | ¥0.84B |
| Equity / assets | 41.2% |
| Operating cash flow | ¥0.02B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | -1644% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
九典制药 ・ 阿石创 ・ 威唐工业 ・ 聚灿光电 ・ 精研科技 ・ 万隆光电 ・ 广哈通信 ・ 永福股份 ・ 英可瑞 ・ 凯伦股份 ・ *ST泉为 ・ 华信新材
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies